Inventory

The components of inventory are summarized as follows:



	As of December 31,
(In millions)	2018		2017
Raw materials	$	196.3	$	162.4
Work in process	606.7		605.7
Finished goods	133.5		157.4
Total inventory	$	936.5	$	925.5

Balance Sheet Classification:
Inventory	$	929.9	$	902.7
Investments and other assets	6.6		22.8
Total inventory	$	936.5	$	925.5

Included in the table above is hemophilia related inventory totaling approximately $180.0 million as of December 31, 2018, which is expected to be sold to Bioverativ in the first quarter of 2019.

Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.

Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $41.9 million, $76.9 million and $48.2 million for the years ended December 31, 2018, 2017 and 2016, respectively.